Patients with cystic fibrosis (CF) 
Patients with cystic fibrosis (CF) often hypoventilate during sleep with marked falls in oxygen saturation (SaO2%). This occurs most commonly during REM sleep, when there is a reduction in rib cage excursion and a fall in end-expiratory lung volume (EELV) . The aim of this study was to examine the effect of nocturnal nasal continuous positive airway pressure (nCPAP) on SaO2 and the respiratory disturbance index (RDI) During all-night polysomnography, patients were monitored continuously, and all variables were recorded simultaneously on a polygraph (model 8-24 E Grass Instruments, Quincy, Mass). Sleep state was recorded with two channels of electroencephalogram (EEG: C3/A2 and C4/Al), two channels of electro-oculogram (ROC/Al and LOC/A2), and one channel of submental EMG. Diaphragm and sternocleidomastoid (SCM) EMGs and ECG leads were placed according to standard technique. Nasal airflow was detected using a pressure transducer (Grass PT5, Quincy, Mass). Rib cage and abdominal movements were measured by inductance plethysmography (Respitrace, Ambulatory Monitoring, Ardsley, NY). The bands were placed around the body such that the midline of the rib cage band lay over the nipples and the midline of the abdominal band lay over the umbilicus. The output of the bands was calibrated with the patient in a supine position by the isovolume technique.14 The rib cage and abdominal signals were summed and used as an estimate of relative tidal volume. The plethysomograph was used in the DC mode, thereby allowing us to examine acute changes in FRC by measuring changes in end-expiratory position of the sum signal. Oxyhemoglobin saturation (SaO2%) was continuously monitored by ear oximetry (Biox 3700e, Boulder, Colo). Transcutaneous CO2 (TcCO2) was continuously monitored (Kontron Microgas 7640 or Radiometer Copenhagen TCM3). CPAP was administered through a nose mask attached to a blower system as previously described from our laboratory.'5
Protocol
Each patient was studied while in a stable clinical condition and participated in two sleep studies within a 10-day period. The protocol consisted of a control sleep study and a study with the addition of nCPAP. Three patients (patients 2, 3 and 7) receiving low-flow oxygen therapy during the daytime were studied on both nights with the addition of supplemental oxygen (1, 1 and 2 L * min-1, respectively). All patients were premedicated with bronchodilator if prescribed.
Patients reported to the laboratory in the late afternoon on the day of the study. Spirometry, flow-volume curves, and lung volume measurements were obtained, and EEG, electro-oculogram, ECG and EMG electrodes were placed in position. Arterial blood gas values were obtained. The patients were allowed their usual suppertime and bedtime medications. At bedtime, the plethysmograph bands were positioned over the thorax and abdomen, taped in place, and the calibration performed. During sleep studies, patients were monitored from lights out at approximately 11 PM until awakening in the morning usually at 6 AM.
Description of Sleep Study Measurements and Definitions
Sleep recordings were scored in 60-s epochs and staged according to standard criteria.16 The respiratory disturbance index (RDI) was defined as the number of apneas and hypopneas per hour of sleep. Apnea was defined as cessation of airflow for at least l0 s with 02 desaturation undefined or cessation of airflow for less than 10 s (but at least one respiratory cycle) if associated with an 02 desaturation of more than 4%. Hypopnea was defined as a reduction in amplitude of airflow or thoracoabdominal wall movement of greater than 50% of the baseline measurement for more than 10 s (02 desaturation need not occur) or the same reduction with an accompanying 02 desaturation of at least 4% (no time limit). These respiratory events were defined as obstructive if they occurred in association with continued diaphragm EMG activity and thoracoabdominal wall movement. Central events were defined as those accompanied by absence of diaphragm EMG activity and thoracoabdominal wall movement. Sleep efficiency was defined as the percentage of total sleep time (TST) over total monitoring time. Total sleep period was defined as TST minus the sleep latency. The number of arousals and the number of episodes of cough per hour of sleep were calculated by dividing the number of arousals and cough by the TST. The mean minimum oxyhemoglobin saturation (MMOS) was calculated by taking the mean of the minimum saturation for each minute of sleep. The mean maximum carbon dioxide tension (MMCO2) was calculated in a similar fashion. The minimum SaO2 or maximum TcCO2 refers to the absolute minimum SaO2 or maximum CO2 in the whole sleep period or in a particular sleep stage.
Statistical Analysis
All data from control and nCPAP sleep studies were compared using a paired t test. All results unless otherwise stated are presented as mean ± SD. A p value <0.05 was considered signif- 
RESULTS
Anthropometric, pulmonary function, and arterial blood gas data for all patients are presented in Table  1 The group data for sleep architecture, arousal, and cough index during the control sleep study are summarized in Table 3 . Cough (3 ±2/h) and positional changes contributed to arousals from sleep (7±2 arousals per hour). nCPAP Study Nasal CPAP was titrated to a mean pressure of 11±2 cm H20, ranging from 8 to 16 cm H20.
The MMOS during both NREM (nCPAP 91 ± 3% vs control 88 ± 2%, p<0.05) and REM sleep (nCPAP 89±6% vs control 83±6%, p<0.05) were significantly improved with the addition of nCPAP when compared with the control study in all patients (Fig  1) . The absolute minimum SaO2% during sleep was also significantly improved by nCPAP (nCPAP 84 ± 7% vs control 76 ± 10%, p<0.05). Nasal CPAP resulted in significantly less percent of TST being FIGURE 2. This is part of the sleep record of patient 6 during the control sleep study in non-REM sleep. Note the consistent activity of the SCM as an accessory muscle with each breath during non-REM sleep. SaO2 is maintained at 88%. spent with low oxyhemoglobin saturations, in particular below 85% (Fig 4) . The addition of nCPAP had no significant effect on TcCO2 during NREM sleep, REM sleep, or on the maximum TcCO2 value when compared with the control study.
As was observed during the control study, the transition from non-REM to REM sleep was associated with a decrease in the tonic activity of the diaphragm and SCM muscle EMG signals. The resultant decrease in the end-expiratory position of the plethysmograph sum signal observed in all patients during the control study was less evident during the use of nCPAP. The amplitude of excursion and endexpiratory position of the plethysmograph sum signal was also maintained during periods of phasic eye movements. This resulted in a marked decrease in the number of hypopneic periods and also a reduction in the desaturation associated with these hypopneic periods (Figs 5 and 6 ). The RDI was significantly reduced by nCPAP in NREM sleep and especially so during REM sleep ( Table 2) .
The group data for sleep architecture, arousal, and cough index during the nCPAP sleep study compared with the control study are summarized in Table 3 Nasal CPAP caused an increase in cough and arousal in one patient but for the group no significant differences were observed (Table 3) . In five of the seven patients, one night of nCPAP was associated with an improvement in sleep efficiency, a reduction in sleep latency, time spent awake and in stage 1/2 sleep, and an increase in SWS (stage 3/4) and REM sleep as a percentage of the total sleep period. Subjectively, quality of sleep was reported as "the same as usual" in two patients and "better than usual" in three patients. The other two patients in our study group had less satisfactory nights on nCPAP. One patient had pressure escaping from the mouth and was forced to use a chin strap, whereas in the other patient, nCPAP resulted in an increase in coughing and subsequent arousal. These events in the two patients resulted in a large increase in their awake time and reductions in their time spent in both SWS and stage REM. Both these patients reported their sleep was "worse than usual." These differing responses meant that as a group nCPAP resulted in a slight but not significant increase in sleep efficiency, but no significant changes in sleep architecture (Table 3) . DISCUSSION The present study demonstrates that in patients with CF and severe lung disease, noctural nCPAP improved oxyhemoglobin saturation during both non-REM and REM sleep and decreased the amount of respiratory disturbance. Nasal CPAP resulted in a significantly less percentage of TST being spent with low oxyhemoglobin saturations. With the addition of nCPAP, episodes of sleep-disordered breathing, especially during phasic REM sleep, were reduced, was not a similar decline in the plethysmograph sum signal when the patients were receiving nCPAP, suggesting that EELV is maintained by nCPAP in these patients, especially during REM sleep. Thus, nCPAP may improve nocturnal oxygenation by preventing a reduction of lung volume and airway closure during REM sleep. Nasal CPAP has also been shown to improve oxygenation and lung mechanics in patients recovering from acute respiratory failure, and to prevent the decrease in EELV in patients recovering from abdominal surgery.22 While nCPAP may relieve airway obstruction, the increase in EELV may also increase the elastic load to breathing. These opposing effects may explain why there was no net reduction in TcCO2 with nCPAP in our study.
A second possible explanation for the observed benefits with nCPAP is that oxygenation was improved as a result of the reduction in the work of breathing. Martin 28 There is an increase in upper airway resistance during sleep in normal subjects and in patients with chronic airflow limitation. [29] [30] [31] This may add an additional load to ventilation and to the muscles of inspiration, especially in the patients with COPD. Nasal CPAP has been shown to reduce upper airway resistance.32 Chan and colleagues33 have shown improvement in both nocturnal and daytime peak expiratory flow rates in patients with asthma and obstructive sleep apnea following nocturnal nCPAP. Interestingly, in a recent study of nCPAP in nonapneic nocturnal asthma, the use of CPAP was associated with a worsening of sleep architecture. 34 It is possible that the two patients who did not sleep well on their first night of nCPAP may have tolerated it better with more prolonged use. A number of our patients claimed a subjective improvement in the quality of sleep even with the first night of use and most of these have continued on nCPAP long term. In five of our seven patients, nCPAP led to a decrease in time spent awake and an increase in time spent in SWS and REM sleep. Although the preliminary results in this small group of patients are encouraging, not all patients tolerated nCPAP well in this single-night study; also, the order of studies was not randomized and therefore limited conclusions can be drawn in regard to patient tolerance and the effect of nCPAP on sleep quality.
The benefits of nocturnal nCPAP are of potential clinical relevance in patients with CF and severe lung disease in view of the significant improvement in oxyhemoglobin saturation and the reduction in respiratory disturbance. The use of nCPAP has also proved to be of additional benefit in preventing nocturnal desaturation and respiratory disturbance in a number of patients already using supplemental oxygen. A long-term controlled trial of nCPAP is needed in patients with CF to determine its effect on mortality, frequency of hospitalization, progression of disease, and quality of life.
